Specialized Human IgG1, IgG2, and Mouse IgG2a vectors designed to tune or eliminate classical complement pathway activation. Includes C1q-enhancing mutations (WS, HexaBody, HexaBody-Extended) that drive cell-surface hexamerization and robust Complement-Dependent Cytotoxicity (CDC), as well as complement-silent variants (SEHF, K322A, CompNull) for precise immunomodulatory applications.
Showing all 7 results